Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1979-1993
Open Access | Times Cited: 18

Showing 18 citing articles:

Mucosal immune response in biology, disease prevention and treatment
Xiaoxue Zhou, Yuchen Wu, Zhipeng Zhu, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections
Michael Y.T. Chow, Harry W. Pan, Han Cong Seow, et al.
Trends in Pharmacological Sciences (2022) Vol. 44, Iss. 2, pp. 85-97
Open Access | Times Cited: 14
Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders
Federica Moraca, Simona Marzano, Francesco D’Amico, et al.
Chemical Communications (2022) Vol. 58, Iss. 85, pp. 11913-11916
Open Access | Times Cited: 13
Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
Daniele Focosi, Fabrizio Maggi
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 6
Inhalable antibodies for the treatment of COVID-19
Zhenlin Yang, Cheng Li, Yuanlin Song, et al.
The Innovation (2022) Vol. 3, Iss. 6, pp. 100328-100328
Open Access | Times Cited: 9
Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing
Jorge L. Arias-Arias, Silvia Molina‐Castro, Laura Monturiol-Gross, et al.
Biotechnology Reports (2022) Vol. 37, pp. e00780-e00780
Open Access | Times Cited: 8
Plant-derived single domain COVID-19 antibodies
Andrew M. Shen, Obeid M. Malekshah, Natalia Pogrebnyak, et al.
Journal of Controlled Release (2023) Vol. 359, pp. 1-11
Open Access | Times Cited: 3
Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants
Nivya Mendon, Rayees A. Ganie, Shubham Kesarwani, et al.
Journal of Biological Chemistry (2022) Vol. 299, Iss. 1, pp. 102732-102732
Open Access | Times Cited: 6
Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys
Jilei Jia, Zhaojuan Yin, Xiao Zhang, et al.
Pharmaceutical Research (2022) Vol. 39, Iss. 9, pp. 2191-2201
Open Access | Times Cited: 5
Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review
Nidhi Garg, Ananya Sree Kunamneni, Pankaj Garg, et al.
Canadian Journal of Infectious Diseases and Medical Microbiology (2023) Vol. 2023, pp. 1-8
Open Access | Times Cited: 2
Development of a potent recombinant scFv antibody against the SARS-CoV-2 by in-depth bioinformatics study: Paving the way for vaccine/diagnostics development
Fatemeh Yaghoobizadeh, Mohammad Roayaei Ardakani‬, Mohammad Mehdi Ranjbar, et al.
Computers in Biology and Medicine (2024) Vol. 170, pp. 108091-108091
Closed Access
Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: effect on virus-induced COX-2 expression
Caterina Tramontozzi, Anna Riccio, Silvia Pauciullo, et al.
Journal of Virus Eradication (2024) Vol. 10, Iss. 3, pp. 100387-100387
Open Access
A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview
Noémie Alphonse, Thomas Sécher, Nathalie Heuzé-Vourc’h
Expert Opinion on Drug Delivery (2024)
Closed Access
Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
Sigifredo Pedraza‐Sánchez, Adrián Cruz-González, Oscar Palmeros-Rojas, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 1
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery
Ferdinando Maria Milazzo, Antonio Chaves-Sanjuán, Olga Minenkova, et al.
Molecular Therapy (2022) Vol. 31, Iss. 2, pp. 362-373
Open Access | Times Cited: 1
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery
Ferdinando Maria Milazzo, Antonio Chaves-Sanjuán, Olga Minenkova, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins
Delphine Antoine, Moein Mohammadi, Chloe E. McDermott, et al.
Frontiers in Nanotechnology (2022) Vol. 4
Open Access
Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein
Sara Lopes van den Broek, Rocío García‐Vázquez, Ida Vang Andersen, et al.
Frontiers in Nuclear Medicine (2022) Vol. 2
Open Access
Page 1

Scroll to top